Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07895914
Recruiting Observational

Validation of the D-TAP Parental Questionnaire for Early Screening of Pediatric Feeding Disorder in Hospitalized Children Aged 8 to 18 Months

NCT07895914 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2026-02-06
Last updated
2026-10-26

Condition(s) studied

Pediatric Feeding DisorderFeeding Difficulties in Infants and Young Children

Study summary

This single-center observational study aims to evaluate the validity of the D-TAP parental questionnaire for early screening of pediatric feeding disorder (PFD) in hospitalized children aged 8 to 18 months. Currently, no standardized screening test is routinely used by all healthcare professionals in France to identify PFD, despite its reported prevalence and potential consequences for child development, family well-being, and healthcare costs.

The D-TAP questionnaire will be compared with the Montreal Children's Hospital Feeding Scale. A blinded clinical speech-language pathology assessment of information collected during a semi-structured parental interview will be used to identify signs suggestive of PFD.

A total of 100 children will be included. The study will assess the diagnostic performance of the D-TAP questionnaire, identify an optimal screening threshold, and explore whether parents initiate contact with a community-based speech-language therapist within six weeks after being informed of signs suggestive of PFD.

Eligibility

Sex
ALL
Min age
8 Months
Max age
18 Months
Healthy volunteers
No
Inclusion Criteria: * Children aged 8 to 18 months, inclusive, receiving care within the pediatric medical-surgical department at the Hautepierre site. * Children born at or after 37 weeks of gestation. Parents who are French-speaking. * Parents affiliated with a social security or health insurance scheme. * Parents who have agreed to participate in the study. Exclusion Criteria: * Parents who refuse participation. * Children diagnosed with a neurodevelopmental disorder. * Children with oromyofacial malformations. * Children with digestive conditions affecting oral feeding, including esophageal achalasia, esophageal atresia, necrotizing enterocolitis, gastroschisis, Hirschsprung disease, eosinophilic esophagitis, omphalocele, chronic intestinal pseudo-obstruction, or short bowel syndrome. * Children with neurological conditions affecting feeding, including pediatric stroke, spinal muscular atrophy, developmental and epileptic encephalopathies, congenital myopathies, cerebral palsy, CHARGE syndrome, congenital myasthenic syndromes, Prader-Willi syndrome, Rett syndrome, Smith-Lemli-Opitz syndrome, traumatic brain injury, or trisomy. * Children with a history of prolonged hospitalization or invasive care during the neonatal period. * Children currently receiving or previously having received artificial nutrition, whether enteral or parenteral.

Primary outcome measure(s)

  • Diagnostic Validity of the D-TAP Parental Questionnaire — During the 10-month data collection period, from February 6, 2026, to April 6, 2027.
    Area under the receiver operating characteristic (ROC) curve calculated from D-TAP questionnaire scores, using a blinded clinical speech-language pathology assessment of the parental interview to identify signs suggestive of pediatric feeding disorder.

Trial sites (1)

FacilityCityRegionStatus
Pediatric Surgery Department, Hautepierre Hospital, University Hospital of Strasbourg, France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers Active, not recruiting
Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease Recruiting
Impact of Perioperative Organ Resuscitation of Brain-dead Deceased Organ Donor on Kidney Graft Function in the Recipient Recruiting
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07895914 on ClinicalTrials.gov ↗ ← All trials in France